WSO - July 2023 - 703

Dittrich et al
703
Fourth-as we included patients treated both before and
after the publication of the DEFUSE-3 and DAWN trials-
we observed changes in diagnostic and treatment over time.
After the publication of the DEFUSE-3 and DAWN trials,
the use of CT-P increased and the administration of i.v. tPA
decreased in our cohort. Since our multivariable regression
models were adjusted for ischemic core volume and preMT
administration of i.v. tPA, we do not expect our results
to have been substantially influenced by these factors.
Conclusion
Among adult patients with LVO treated with MT between
6 and 24 h, the rates of sICH, all-cause mortality, and
favorable
functional outcome
were
similar
between
DEFUSE-3/DAWN eligible and ineligible patients. Our
data provide a compelling rationale for randomized trials
with more liberal inclusion criteria regarding the presence
of premorbid functional disability, low NIHSS scores at
admission, and vascular occlusions distal to the MCA-M1
segment.
Acknowledgements
The authors thank Inga Lappe and Malin Zahn.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: M.P. has received funds from Medtronic, Stryker,
Penumbra, Phenox, Rapid Medical. He has received speakers
honoraria from Stryker, Penumbra, Acandis, Phenox, Medtronic.
GMDM received speaker honoraria from Medtronic; he declares
no other conflicts of interest related to this work. The remaining
authors report no conflicts of interest related to this work.
Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article: The
University Hospital Basel and the Propatient Research Foundation
funded the study.
ORCID iDs
Tolga D Dittrich
https://orcid.org/0000-0002-9987-3631
Alexandros A Polymeris
2208
Data availability
Anonymized records may be provided upon reasonable request by
the corresponding author.
Supplemental material
Supplemental material for this article is available online.
https://orcid.org/0000-0002-9475References
1.
Berkhemer OA, Fransen PS, Beumer D, et al. A randomized
trial of intraarterial treatment for acute ischemic stroke. N
Engl J Med 2015; 372: 11-20.
2. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy
after intravenous t-PA vs. T-pa alone in stroke. N Engl J
Med 2015; 372: 2285-2295.
3. Goyal M, Demchuk AM, Menon BK, et al. Randomized
assessment of rapid endovascular treatment of ischemic
stroke. N Engl J Med 2015; 372: 1019-1030.
4. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular
therapy for ischemic stroke with perfusion-imaging selection.
N Engl J Med 2015; 372: 1009-1018.
5. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within
8 hours after symptom onset in ischemic stroke. N Engl J Med
2015; 372: 2296-2306.
6. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy
6 to 24 hours after stroke with a mismatch between deficit and
infarct. N Engl J Med 2018; 378: 11-21.
7. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for
stroke at 6 to 16 hours with selection by perfusion imaging. N
Engl J Med 2018; 378: 708-718.
8. Desai SM, Rocha M, Molyneaux BJ, et al. Thrombectomy
6-24 hours after stroke in trial ineligible patients. J Neurointerv
Surg 2018; 10: 1033-1037.
9. Hao Y, Yang D, Wang H, et al. Predictors for symptomatic
intracranial hemorrhage after endovascular treatment of acute
ischemic stroke. Stroke 2017; 48: 1203-1209.
10. Leslie-Mazwi TM, Hamilton S, Mlynash M, et al. DEFUSE 3
Non-DAWN patients. Stroke 2019; 50: 618-625.
11. Siegler JE, Messé SR, Sucharew H, et al. Thrombectomy in
DAWN- and DEFUSE-3-ineligible patients: a subgroup analysis
from the BEST prospective cohort study. Neurosurgery
2020; 86: E156-E163.
12. Dittrich TD, Sporns PB, Kriemler LF, et al. Mechanical
thrombectomy versus best medical treatment in the late time
window in non-DEFUSE-non-DAWN patients-a multicenter
cohort study. Stroke 2022.
13. Maegerlein C, Fischer J, Mönch S, et al. Automated calculation
of the Alberta stroke program early CT score: feasibility
and reliability. Radiology 2019; 291: 141-148.
14. Xiong Y, Huang CC, Fisher M, Hackney DB, Bhadelia RA and
Selim MH. Comparison of automated CT perfusion softwares
in evaluation of acute ischemic stroke. J Stroke Cerebrovasc
Dis 2019; 28: 104392.
15. von Kummer R, Broderick JP, Campbell BC, et al. The
Heidelberg bleeding classification: classification of bleeding
events after ischemic stroke and reperfusion therapy. Stroke
2015; 46: 2981-2986.
16. Hao Y, Zhang Z, Zhang H, et al. Risk of intracranial hemorrhage
after endovascular treatment for acute ischemic stroke:
systematic review and meta-analysis. Interv Neurol 2017; 6:
57-64.
17. Herzberg M, Scherling K, Stahl R, et al. Late thrombectomy
in clinical practice: retrospective application of DAWN/
DEFUSE3 criteria within the German stroke registry. Clin
Neuroradiol 2021; 31: 799-810.
International Journal of Stroke, 18(6)
https://www.orcid.org/0000-0002-9987-3631 https://www.orcid.org/0000-0002-9475
WSO - July 2023

Table of Contents for the Digital Edition of WSO - July 2023
